NR
BMRN icon

Newfound Research’s BioMarin Pharmaceuticals BMRN Stock Holding History

Newfound Research’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$60K Buy
+707
New +$63K 0.15% 101
2020
Q4 		– Sell
-277
Closed -$21K – 132
2020
Q3 		$21K Buy
+277
New +$28K 0.06% 109

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Newfound Research's BMRN Position: Q3 2022 in Review

Newfound Research opened a new position in BioMarin Pharmaceuticals (BMRN) in Q3 2022: 707 shares worth $60K. The stake represents 0.15% of the portfolio and ranks #101 among its holdings. This is a return to the name: Newfound Research previously reported a position in BMRN as recently as Q3 2020.

Newfound Research first reported a position in BMRN in Q3 2020 and has held it in 2 quarters since. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

  • Newfound Research held 707 shares of BioMarin Pharmaceuticals worth $60K as of Q3 2022.
  • BioMarin Pharmaceuticals was a new Newfound Research position in Q3 2022.
  • BioMarin Pharmaceuticals made up 0.15% of Newfound Research's portfolio in Q3 2022, its #101 holding.
  • Newfound Research first reported a position in BioMarin Pharmaceuticals in Q3 2020 and has held it in 2 quarters since.
  • 551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Newfound Research's 13F filing for Q3 2022, filed 13 Oct 2022.